Atea Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is AVIR moving today?
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for AVIR.
AVIR insider activity
Atea Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$275K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | 2026-05-18 | Murphy Polly A. | Insider | buy | $4.17 | 6,100 | 92,145 | $25K | SEC Form 4 |
| 2026-03-13 | 2026-03-11 | Corcoran Andrea | Insider | buy | $1.24 | 60,000 | 823,576 | $74K | SEC Form 4 |
| 2026-02-03 | 2026-02-03 | Sommadossi Jean-Pierre | Insider | buy | $1.24 | 300,000 | 767,830 | $372K | SEC Form 4 |
| 2026-02-03 | 2026-01-31 | Horga Maria Arantxa | Insider | sell | $4.24 | 16,073 | 96,086 | $68K | SEC Form 4 |
| 2026-02-03 | 2026-01-31 | Vavricka John | Insider | sell | $4.24 | 11,570 | 82,594 | $49K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 4 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAVIR contract awards, year to date.
Public federal awards linked to this ticker.
AVIR lobbying filings, year to date.
Registered lobbying filings matched to Atea Pharmaceuticals Inc.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
JEFFREY J. KIMBELL & ASSOCIATES, INC.